ArticlePakistan journal of medical sciences2026
Integrative biochemical and computational analysis identifies LOX-1 and IL-6R as therapeutic targets in oxidative, inflammatory and lipid dysregulation of ischemic stroke.
Article in Pakistan journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Ischemic stroke (IS) being one of the leading causes of mortality and morbidity globally is initiated by complex interactions among lipid peroxidation, oxidative stress and metabolic dysfunction. This study aimed to identify therapeutic targets for these pathological pathways is critical for improving diagnostic and treatment strategies. Methodology: This case control study comprising 150 patients and one hundred healthy controls was conducted at DHQ Hospital, Gujranwala from June 2022 to June 2023. Biochemical analyses quantified apolipoproteins, oxidized lipoproteins (oxLDL, oxHDL), sdLDL, antioxidant factors (SOD), inflammatory (IL-6) and metabolic markers (ferritin, LDH) using ELISA and spectrophotometric assays. Moreover, molecular docking and 100 ns molecular dynamics (MD) simulations conducted to evaluate inhibitory potential and structural stability of selected small molecule ligands targeting major lipid related (LOX-1) and inflammatory (IL-6R) receptors. Results: The stroke patients demonstrated significantly elevated levels of biochemical markers and a marked reduction in SOD activity (p< 0.05). Multivariate regression modeling highlighted oxHDL, apoCIII, ferritin, and LDH as robust independent predictors of ischemic stroke. IL-6 displayed positive correlation with oxidized lipoproteins and apolipoproteins, supporting a link between inflammatory signaling and lipid abnormalities. Computational studies identified strong ligand receptor binding with docking energies ranging from -5.9 to -8.0 kcal/mol. Conclusion: Overall, integrated biochemical and computational approach highlights inflammatory activation, oxidative lipid damage, and iron dysregulation as vital contributors to stroke. Key receptors involved in lipid oxidation and cytokine signaling emerge as promising dual therapeutic targets, and the identified ligands show potential as lead candidates for future drug development against ischemic stroke.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.